These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[ Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891 [No Abstract] [Full Text] [Related]
4. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion. Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254 [TBL] [Abstract][Full Text] [Related]
5. Radiation exposure assessment of nuclear medicine staff administering [ Riveira-Martin M; Struelens L; Muñoz Iglesias J; Schoonjans W; Tabuenca O; Nogueiras JM; Salvador Gómez FJ; López Medina A EJNMMI Phys; 2023 Nov; 10(1):70. PubMed ID: 37962683 [TBL] [Abstract][Full Text] [Related]
12. Response to Single Low-dose Wang H; Cheng Y; Zhang J; Zang J; Li H; Liu Q; Wang J; Jacobson O; Li F; Zhu Z; Chen X Theranostics; 2018; 8(12):3308-3316. PubMed ID: 29930731 [No Abstract] [Full Text] [Related]
13. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108 [TBL] [Abstract][Full Text] [Related]
14. Validation of [Formula: see text]Tc and [Formula: see text]Lu quantification parameters for a Monte Carlo modelled gamma camera. Di Domenico G; Di Biaso S; Longo L; Turra A; Tonini E; Longo M; Uccelli L; Bartolomei M EJNMMI Phys; 2023 Apr; 10(1):27. PubMed ID: 37029829 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of peptide receptor radionuclide therapy with Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603 [No Abstract] [Full Text] [Related]
17. Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [ Plas P; Limana L; Carré D; Thiongane A; Raguin O; Mansi R; Meyer-Losic F; Lezmi S Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145306 [TBL] [Abstract][Full Text] [Related]
18. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Seregni E; Maccauro M; Coliva A; Castellani MR; Bajetta E; Aliberti G; Vellani C; Chiesa C; Martinetti A; Bogni A; Bombardieri E Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):84-91. PubMed ID: 20168290 [TBL] [Abstract][Full Text] [Related]
19. Use of [ Glover M; Caplin M; Leeuwenkamp OR; Longworth L EJC Suppl; 2021 Nov; 16():14-23. PubMed ID: 34912479 [TBL] [Abstract][Full Text] [Related]
20. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Wehrmann C; Senftleben S; Zachert C; Müller D; Baum RP Cancer Biother Radiopharm; 2007 Jun; 22(3):406-16. PubMed ID: 17651048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]